Clinical importance of serum interleukin‐18 and nitric oxide activities in breast carcinoma patients

Günel, Nazan; Coşkun, Uğur; Sancak, Banu; Günel, Uğur; Hasdemir, Oğuz; Bozkurt, Şükrü

doi:10.1002/cncr.10705

Cited by 68 publications

(58 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Still, IL-18 may presumably be an important marker in the progression of breast cancer, [6] as serum IL-18 levels in breast cancer patients who developed bone metastases were found to be significantly higher in several studies. [7,8] In light of these results, the usefulness of serum IL-18 as a marker of the potential development of bone metastases in breast cancer patients was presently investigated.…”

Section: Discussionmentioning

confidence: 99%

“…In a similar study conducted by Günel et al in 2002, serum IL-18 levels in the metastatic and nonmetastatic groups were found to be higher than those of the healthy group, while serum IL-18 levels of the group with bone metastases were higher than those of the nonmetastatic group. [7] However, in several studies, some performed by Günel et al, breast cancer patients with metastases in other organs constituted a separate study group. Still, serum IL-18 levels of breast cancer patients with bone metastases were statistically significantly higher, compared to those of breast cancer patients with other organ metastases.…”

Section: Discussionmentioning

confidence: 99%

“…Still, serum IL-18 levels of breast cancer patients with bone metastases were statistically significantly higher, compared to those of breast cancer patients with other organ metastases. [7,9] Following the important discovery that primary osteoblasts can also secrete IL-18 receptor components, many authors have suggested that osteoblasts are target cells in IL-18 response and that IL-18 exerts a physiological effect on osteogenic cells. [10] IL-18 exerts its effects on osteoblasts, not via production of INF-y, but rather via production of granulocyte macrophage colony-stimulating factor (GM-CSF).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer

Nayır¹

2016

TJ Oncol

View full text Add to dashboard Cite

OBJECTIVEBreast cancer is a metastatic disease that frequently (in approximately 70% of cases) affects the skeletal system. The aim of the present study was to compare serum IL-18 levels in breast cancer patients with and without bone metastases with healthy controls. METHODSIncluded were a total of 154 female breast cancer patients with bone metastases (n=53; Group 2) and without bone metastases (n=51; Group 1), as well as 50 healthy control subjects (Group 3). Serum IL-18 levels were compared among the groups. RESULTSMean serum IL-18 levels were significantly different between Groups 1 and 3 (p<0.001), Groups 2 and 3 (p<0.001), and Groups 2 and 1 (p=0.020). In receiver operating characteristic (ROC) curve analysis performed between Groups 1 and 2, sensitivity of serum IL-18 levels in patients with bone metastases was nearly 26 percent. CONCLUSIONLower rates of IL-18 sensitivity were detected in breast cancer patients with bone metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer

Nayır¹

2016

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…It can raise the immune protection against cancer cells by energizing and stimulating the IFN-γ creation and therefore has a key role in Th1 response [8]. It has been made known that IL-18 has a major role in the progression of the tumor.…”

Section: Discussionmentioning

confidence: 99%

“…IL-18 can organize both adaptive and innate immune responses during its impacts on natural killer (NK) cells, dendritic cells, monocytes, B-cells, and T-cells [8]. It can increase the immune resistance toward tumor cells by energizing and stimulating the interferon (IFN-γ) production and therefore has a key role in Th1 response [8].…”

Section: Introductionmentioning

confidence: 99%

Interleukin-18 Gene Polymorphism and Some Risk Factors in Iraqi Patients With Breast Cancer

Al-Askeri

Jabir²,

Jaber³

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Breast cancer is the most diagnosed cancer in women, which leads to death in a lot of women with breast cancer. The major risk factors associated with breast cancer risk related to family history, age, clinical history, lifestyle factors, long-period hormonal exposure, and single nucleotide polymorphisms in many genes showed possible links with breast cancer incidence risk in different people populations. Our study aimed to figure out the correlation between smoking, lodging and family history, and other factors with the risk of breast cancer.Methods: Blood sample from female patients with breast cancer and healthy individuals were collected and subjected to tetra-amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) technique for −607 C/A mutation of an interleukin (IL-18) gene and SPSS 18 software analyzed the results statically. Results:Results showed no association between lodging and smoking with risk of breast cancer, (p>0.05), while the association between the risk and family history were obvious (p<0.05). Conclusion:The results obtained by T-ARMS-PCR technique did not show the association between −607 C/An alternation of IL-18 gene and breast cancer (p>0.05) in the individuals examined in our study.

show abstract

IL‐18 is produced by prostate cancer cells and secreted in response to interferons

Lebel‐Binay

Thiounn

Pinieux

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

Key words: IL-18; caspase-1; prostate cancer; prognosis; IFN-␥; IFN-␣IL-18 was first identified as an IGIF based on its ability to induce high levels of IFN-␥ secretion by both NK cells and Th1 clones. 1,2 IL-18 belongs to the IL-1 family, 3 lacks a signal sequence 2 and is processed into an 18 kDa mature form by caspase-1. 4 It is mainly produced by macrophages and dendritic cells. However, we and others have shown that IL-18 is also synthesized by nonimmune cells. 5 IL-18 potentiates IL-12-induced Th1 development 6,7 and plays an important role in T-cell proliferation. 2 In addition, it enhances FasL-mediated cytotoxicity of NK cells and Th1 cells 8,9 and has proinflammatory properties by inducing chemotactic molecules for macrophages, polymorphonuclear neutrophils and inflammatory cytokines such as TNF-␣ or IL-1␤. 10 -12 Murine models have demonstrated the antitumor activity of IL-18, either by systemic administration 13,14 or in tumors genetically modified to constitutively express IL-18. 15 Antitumor effects are mediated by IL-18-induced IFN-␥, NK cells and T CD4 ϩ Fas-dependent cytotoxicity. [13][14][15][16] In vitro, IL-18 added to cultures of tumor cells, NK cells, dendritic cells and T cells induces tumor cell death by enhancing NK cell cytotoxicity, which activates dendritic cells to promote a specific CTL response. 17 This could position IL-18 as an important bridge between innate and adaptive antitumor immune responses. Some antitumor effects of IL-18 may also be mediated via nonimmunologic mechanisms as IL-18 has antiangiogenic properties in vitro and immunohistochemistry studies have revealed hypovascularization of IL-18-treated tumors. 15,18 Little is known about the in vivo presence of IL-18 in human tumors. In a previous study, we observed that IL-18 protein was expressed at various levels in colon cancers and that loss of transcripts at the tumor site of the 2 downstream targets of IL-18, i.e., IFN-␥ and FasL, was associated with the concomitant presence of distant metastases. 19 These results suggested a role of IL-18 in the control of tumor spreading in humans, in line with the antitumor properties of IL-18 observed in murine models.Research in prostate cancer has focused on the role of IFN-␥ in tumor progression. In vitro, IFN-␥ causes cycle arrest of prostate tumor cell lines, induces the cyclin-dependent kinase inhibitor p21 WAF1 , downregulates neu/HER-2 20 and decreases the metastatic potential of some prostate cancer cell lines. 21 IFN-␥ is produced by stromal and epithelial cells in normal prostate and prostate cancers, 22 and analysis of the transcriptional profile of prostate cancers by Affymetrix (Santa Clara, CA) Genechip technology has shown that about 30% of malignant tumors present downmodulation of IFN-␥-inducible molecules. 23 This may indicate modulation of IFN-␥ in tumors, but no information is available about the existence of the IFN-␥-inducing cytokine IL-18 in normal prostate and prostate cancers. We therefore investigated the IL-18 status of prostate cancers and its as...

show abstract

Clinical importance of serum interleukin‐18 and nitric oxide activities in breast carcinoma patients

Cited by 68 publications

References 30 publications

Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer

Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer

Interleukin-18 Gene Polymorphism and Some Risk Factors in Iraqi Patients With Breast Cancer

IL‐18 is produced by prostate cancer cells and secreted in response to interferons

Contact Info

Product

Resources

About